PART I Company Overview We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients. We aim to develop diff...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001590750-26-000007 | EDGAR | 101K words |
| 2025-03-03 | 2024-12-31 | 0001590750-25-000004 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001590750-24-000007 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0001590750-23-000002 | EDGAR | — |
| 2022-03-11 | 2021-12-31 | 0001590750-22-000004 | EDGAR | — |
| 2021-03-26 | 2020-12-31 | 0001590750-21-000029 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001590750-20-000021 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001590750-19-000013 | EDGAR | — |
| 2018-03-15 | 2017-12-31 | 0001590750-18-000006 | EDGAR | — |
| 2017-03-24 | 2016-12-31 | 0001171843-17-001747 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001590750-25-000020 | EDGAR | 62K words |
| 2025-08-06 | 2025-06-30 | 0001590750-25-000012 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001590750-25-000008 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001590750-24-000023 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001590750-24-000019 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001590750-24-000012 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001590750-23-000013 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001590750-23-000008 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001590750-23-000003 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001590750-22-000012 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001590750-22-000009 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001590750-22-000007 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001193125-26-130433 | EDGAR | 9K words |
| 2026-02-26 | 0001193125-26-073391 | EDGAR | — |
| 2025-11-05 | 0001193125-25-265711 | EDGAR | — |
| 2025-10-23 | 0001193125-25-247410 | EDGAR | — |
| 2025-10-21 | 0001193125-25-245206 | EDGAR | — |
| 2025-10-20 | 0001193125-25-243039 | EDGAR | — |
| 2025-08-06 | 0001193125-25-173983 | EDGAR | — |
| 2025-07-30 | 0001193125-25-168614 | EDGAR | — |
| 2025-06-24 | 0001193125-25-145741 | EDGAR | — |
| 2025-05-20 | 0001193125-25-122821 | EDGAR | — |
269 total filings indexed. 237 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001590750 |
| Ticker | VRDN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.viridiantherapeutics.com |
| Listed | 2014-06-18 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report